secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-205117
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics Q1 revenue $34.5M (+8% YoY); net loss improves; maintains FY2026 outlook
--------------------------------------------------------------------------------

- Revenue $34.5M (+8% YoY); U.S. clinic revenue $21.5M (+15%) on Greenbrook acquisition and SPRAVATO expansion.
- Net loss $(10.8M) ($0.16/shr) vs $(12.7M) loss a year ago; operating expenses down 6% to $25.1M.
- Cash $19.0M (incl. $5.8M restricted); made $5M debt principal payment in March to reduce debt.
- Optum/UHC/UBH expanded TMS policy to allow nurse practitioners to order/administer NeuroStar, covering 34.8M lives across 26 states.
- FY2026 guidance: revenue $160-166M, gross margin 47-49%, op ex $100-105M, cash from ops negative $13-17M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000119312526205117/0001193125-26-205117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000119312526205117/d139145d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-205117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer